---
layout: default
title: Rocuronium
parent: 僅模型預測 (L5)
nav_order: 298
evidence_level: L5
indication_count: 10
---

# Rocuronium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Rocuronium: From Surgical Anesthesia to Migraine Disorder

## One-Sentence Summary

Rocuronium is a non-depolarizing neuromuscular blocking agent (NMBA) widely used perioperatively to facilitate tracheal intubation and maintain skeletal muscle relaxation during surgery.
The TxGNN model predicts it may be effective for **Migraine Disorder**, but with only **1 pharmacokinetic observation trial** (grade C relevance) and **no supporting publications**, the prediction lacks direct clinical or mechanistic backing.
This case is assessed as a likely knowledge-graph false positive — the high model score does not reflect biological plausibility.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Neuromuscular blockade for surgical anesthesia |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Rocuronium competitively antagonizes nicotinic acetylcholine receptors (nAChR) at the skeletal neuromuscular junction, blocking nerve-to-muscle signal transmission and producing dose-dependent muscle relaxation. It does not cross the blood-brain barrier and exerts no clinically meaningful central nervous system effects.

Migraine pathophysiology is driven by distinct and independent pathways: calcitonin gene-related peptide (CGRP) release from trigeminal nerve terminals, cortical spreading depression (CSD), serotonergic dysregulation (5-HT), and central sensitisation. None of these mechanisms intersect with peripheral nAChR blockade at the neuromuscular junction. The drug's route of administration (IV bolus in operating room settings) is also fundamentally incompatible with outpatient migraine management.

The high TxGNN score (99.90%) most likely reflects an indirect multi-hop path in the knowledge graph — Rocuronium → nAChR → calcium channel nodes → migraine susceptibility genes — rather than a direct pharmacological relationship. This type of indirect graph inference is a recognised source of false-positive predictions in graph-based drug repurposing models and requires mechanistic or clinical corroboration before further investigation.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01431326](https://clinicaltrials.gov/study/NCT01431326) | N/A | Completed | 3,520 | Paediatric pharmacokinetics study of understudied drugs administered per standard of care; Rocuronium included as a routine anaesthetic agent, not studied for migraine treatment. No therapeutic relevance to migraine. |

---

## Literature Evidence

Currently no related literature available.

---

## Philippines Market Information

Rocuronium is currently **not registered** with the Philippines FDA. No active product licences are on record (total registrations: 0).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a very high TxGNN model score, Rocuronium's mechanism of action — peripheral skeletal muscle nAChR blockade — has no established pharmacological connection to migraine pathophysiology (CGRP, CSD, trigeminal vascular, or serotonergic pathways). The evidence base is L5 (model prediction only), with no published studies or trials targeting this indication. The drug is also not marketed in the Philippines and requires intravenous hospital administration, making the proposed indication structurally incompatible without a fundamentally different formulation.

**To proceed, the following would be needed:**
- A peer-reviewed biological hypothesis directly linking peripheral nAChR blockade to migraine attenuation (none identified in literature search)
- Preclinical data (animal models of migraine) demonstrating measurable anti-migraine effects from Rocuronium or structurally related NMBAs
- Resolution of route-of-administration incompatibility: current IV-only formulation is unsuitable for outpatient migraine therapy; a novel delivery route would require full de novo development
- Philippines FDA registration — baseline regulatory prerequisite for any clinical development pathway
- Package insert review (TFDA or equivalent) to assess safety warnings and contraindications before any further evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

